ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1195

The Relations of Analgesic Antidepressants Use to Knee or Hip Replacement Among Osteoarthritis Patients Compared to Selective Serotonin Reuptake Inhibitors in a Large Prospective Cohort
Abstract Number: 1196

Relation of Different Types of Antidepressants Use to Pain Severity and Measures of Pain Sensitization in Kneeosteoarthritis
Abstract Number: 1197

Safety and Immunogenicity of an Active Anti-IL-6 Immunotherapy in a Phase 1 Clinical Trial in Knee Osteoarthritis Patients
Abstract Number: 1198

Impact of Metabolic Syndrome on Knee Osteoarthritis Severity and Progression: A PROCOAC Cohort Study
Abstract Number: 1199

Diclofenac Sodium 1% Gel Improves Physical Function in the Performance of Important Activities of Daily Living in Patients with Hand or Knee Osteoarthritis
Abstract Number: 1200

Prevalence and Joint Involvement Patterns of Erosive and Non-erosive Hand Osteoarthritis in the General Population in China
Abstract Number: 1201

Association of COVID-19 Vaccinations with Osteoarthritis Flares: A Case-Crossover Study
Abstract Number: 1202

Harnessing MicroRNA and Machine/Deep Learning for Early Prediction of Knee Osteoarthritis Structural Progression
Abstract Number: 1203

My Shoulder Hurts, What Should I Do? A Systematic Review and Bayesian Network Meta-analysis of Different Injectables in Glenohumeral Osteoarthritis
Abstract Number: 1204

Immunobased Profiling of Knee Osteoarthritis Patients to Predict Response to Regenerative Treatment with Autologous Blood-derivative Platelet-Rich Plasma Injection
Abstract Number: 1205

OARSI Initiative to Develop Classification Criteria for Early-Stage Symptomatic Knee OA (EsSKOA): What Should Be Considered in the Differential Diagnosis of EsSKOA?
Abstract Number: 1206

Association of Effusion-synovitis on Knee Pain in Early and Later-stage Knee Osteoarthritis
Abstract Number: 1207

Patterns of Shared Variation in Knee Ultrasound for Osteoarthritis: A Machine Learning Approach
Abstract Number: 1208

Statin Use and Risk of Total Joint Replacement of Knee and Hip in Osteoarthritis Patients: Study Based on the French National Health Insurance Cohort
Abstract Number: 1209

Time to Knee Replacement by Kellgren-Lawrence Grade and Presence of Frequent Knee Pain in Two Large and Diverse Longitudinal Cohorts: Data from MOST and OAI

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].